Cutaneous Lupus
14
4
4
7
Key Insights
Highlights
Success Rate
70% trial completion
Clinical Risk Assessment
Based on trial outcomes
High Risk
Score: 64/100
21.4%
3 terminated out of 14 trials
70.0%
-16.5% vs benchmark
14%
2 trials in Phase 3/4
57%
4 of 7 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 7 completed trials
Clinical Trials (14)
Identification of Cutaneous and Blood Biomarkers Predictive of Response to Systemic Treatments During Chronic Inflammatory Skin Diseases
Characterizing Adherence to Treatment and Satisfaction With Care in Patients With Cutaneous Lupus
Open-label Study of Tofacitinib for Moderate to Severe Skin Involvement in Young Adults With Lupus
Maternal Autoimmune Disease Research Alliance (MADRA) Registry
Duke Lupus Registry
Evaluation of Tofacitinib in Prevention of Photosensitivity in Lupus
Determinants of Chronic Inflammatory Skin Disease Trajectories
Cutaneous Lupus Medication Experience Study
Relevance of Monitoring Blood and Salivar Levels of Drugs Used in Rheumatic Autoimmune Diseases
Study of the Efficacy of 532nm Laser and 1064 nm Laser in the Treatment of Cutaneous Lupus Erythematous Versus Topical Corticosteroids Alone
Duke Autoimmunity in Pregnancy Registry
Safety Study of AMG 811 in Subjects With Discoid Lupus Erythematosus
Safety Study of AMG 557 in Subjects With Subacute Cutaneous Lupus Erythematosus
Study To Evaluate The Safety And Efficacy Of Lenalidomide For Refractory Cutaneous Lupus